Ground News

Don't Just Read the News, Understand It.

biopharmadive.com image

News from biopharmadive.com

See all of biopharmadive.com news coverage in one place. Discover how biopharmadive.com’s media bias informs their coverage and compare with thousands of other news outlets.

Overall, we’ve indexed 228 stories from biopharmadive.com over the past 3 months.

The Ground News media bias check for biopharmadive.com is Center. Scores are assigned by aggregating bias scores from Ad Fontes Media, Media Bias/Fact Check, and All Sides.

biopharmadive.com’s aggregated factuality score is High. Factuality is assigned by combining fact check, credibility, and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Information about biopharmadive.com

Where is biopharmadive.com located?biopharmadive.com's Website

Media Bias Ratings

Average Bias Rating:

Center

Center

byMedia Bias/Fact Check

Do you diasgree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top biopharmadive.com News

RFK Jr.’s CDC vaccine panel backs Merck RSV shot for infants

CDC · United States

RFK Jr.’s CDC vaccine panel backs Merck RSV shot for infants

66% Center coverage: 59 sources

Robert F. Kennedy Jr.’s revamped government panel of outside vaccine advisors on Thursday recommended the use of Merck’s shot to protect infants from respiratory syncytial virus, a temporary reprieve for public health officials and companies concerned about the Health and Human Services secretary’s immunization policy.See the Story

Experimental Moderna Flu Shot More Effective than Approved Vaccine, Company Says

Vaccines · United States

Experimental Moderna Flu Shot More Effective than Approved Vaccine, Company Says

64% Center coverage: 31 sources

AbbVie’s $2.1B Acquisition Adds In Vivo Cell Therapy to Its Immunology & Inflammation Pipeline

AbbVie’s $2.1B Acquisition Adds In Vivo Cell Therapy to Its Immunology & Inflammation Pipeline

87% Center coverage: 8 sources

AbbVie is acquiring Capstan Therapeutics, a startup with technology that enables in vivo engineering of immune cells. The University of Pennsylvania spinout’s lead program recently began a Phase 1 test as a potential treatment for B cell-mediated autoimmune disorders. The post AbbVie’s $2.1B Acquisition Adds In Vivo Cell Therapy to Its Immunology & Inflammation Pipeline appeared first on MedCity News.See the Story

Psychedelic Nasal Spray Shows Promise Against Depression

100% Center coverage: 7 sources

Mebufotenin benzoate also requires a much shorter period of clinical supervision in trialFDA See the Story

Organon Stops Work on Endometriosis Drug After Failure in Phase 2 Test

100% Center coverage: 3 sources

Organon said OG-6219 did not beat a placebo in a mid-stage clinical trial whose main goal was to measure the change in pelvic pain caused by endometriosis. The twice-daily pill came from Organon’s 2021 acquisition of Forendo Pharma. The post Organon Stops Work on Endometriosis Drug After Failure in Phase 2 Test appeared first on MedCity News.Pharma See the Story

Acadia CEO sets sights on ‘much more assertive’ deals to invigorate pipeline

100% Center coverage: 1 sources

Industry veteran Catherine Owen Adams expects external innovation will be key to getting the brain-focused drug developer to “the next level.”Innovation · United States Read Article

Regeneron Bispecific Approved for Myeloma; Concentra to Buy IGM

100% Center coverage: 1 sources

Lynozyflic is one of two bispecific antibodies Regeneron hopes will lift its oncology business. Meanwhile, IGM is the latest struggling biotech to agree to a buyout deal from Concentra.See the Story

Sage to Lay Off Most Staff Amid Supernus Buyout

100% Center coverage: 2 sources

The biotech, which agreed to be bought by Supernus after clinical and commercial struggles, plans to lay off 338 employees by late August.United States · United States See the Story

Sodium Channel Blockers for Pain: New Opportunities After Vertex’s ‘Watershed’ Moment

100% Center coverage: 1 sources

The success of Vertex's opioid alternative Journavx could aid a group of biotechs that aim to take a similar path with NaV1.8 and NaV1.7 inhibitors.San Diego · San Diego See the Story

Acadia’s ‘Very Bullish’ Sales Forecast Restores some Confidence on Wall Street

100% Center coverage: 1 sources

The brain drug developer is now saying that its two marketed products could ultimately bring in $2 billion annually, and its pipeline may one day add another $12 billion in sales each year.Wall Street See the Story

Kennedy's vaccine committee endorses preservative-free fall flu shots

49% Center coverage: 113 sources

The Advisory Committee on Immunization Practices (ACIP), recently remade by Health and Human Services Secretary Robert F. Kennedy Jr., voted Thursday in favor of only recommending flu shots that don’t contain the mercury-based preservative thimerosal. Vaccines · United States See the Story

Breaking News Topics Related to biopharmadive.com